A tyrosine kinase inhibitor which acts on EGFR, inhibiting EGFR-associated kinase activity (IC50 = 2.5 µM) and tumor growth in human HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg; drug form of Erlotinib, Tarceva™, is used to treat certain forms of cancer.